GSKCH resumes production of Nicorette mini Lozenge

PARSIPPANY, N.J. — GlaxoSmithKline Consumer Healthcare on Monday announced that 2- and 4-mg Nicorette mini Lozenge is now available at most retail location in the United States following a shortage in supply.

 

In early February 2014, the company issued a voluntary recall on all nicotine lozenges produced at a site in Aiken, S.C. after manufacture ring issues affected some batches. In some instances, the lozenges were larger or smaller than GSKCH’s manufacturing standards. After correcting the issues and improving quality measures, production of the product has resumed, the company said. 

 

"The safety and well-being of our consumers is our number one priority and we did not compromise on the somewhat lengthy corrective actions that needed to be taken," said Sue Kelsey, GlaxoSmithKline Consumer Healthcare Marketing Director, Wellness & Skin Health Brands. "We understand what a life-changing event stopping smoking can be and, at the same time, how incredibly difficult it can be to get there. For those looking for help, we hope that the return to market of Nicorette mini Lozenge and our online information can help to provide the tools and inspiration to get smokers towards their goals."  

 

Nicorette mini Lozenge is a stop-smoking lozenge that, according to GSKHC, can double a smoker’s chances of kicking the habit. The lozenge comes in a pocket-size vial so smokers can it readily available to deal with craving and withdrawal symptoms. Other GSKCH nicotine replacement therapy products include Nicorette gum and NicoDerm CQ.